From Pharmacogenomics to Translational Biomarkers

  • Donna L. Mendrick
Part of the Methods in Molecular Biology™ book series (MIMB, volume 460)


There is a need for new biomarkers to enable faster detection of adverse events due to drugs and disease processes. One would prefer biomarkers that are useful in multiple species (i.e., translational or bridging biomarkers) so that it would be possible to directly link responses between species and follow such injury in both preclinical and clinical settings. This chapter will explore some of the issues surrounding the use of pharmacogenomics to identify and qualify such biomarkers, and examples will be provided.


biomarkers pharmacogenomics toxicogenomics translational 


  1. 1.
    Vaidya, V.S. and Bonventre, J.V. (2006) Mechanistic biomarkers forcytotoxic acute kidney injury. Expert. Opin. Drug Metab.Toxicol. 2, 697–713.CrossRefPubMedGoogle Scholar
  2. 2.
    Ichimura, T., Bonventre, J.V., Bailly, V., Wei, H., Hession, C.A., Cate, R.L., and Sanicola, M. (1998) Kidney injury molecule-1(KIM-1), a putative epithelial cell adhesion molecule containing anovel immunoglobulin domain, is up-regulated in renal cells afterinjury. J. Biol. Chem. 273, 4135–4142.CrossRefPubMedGoogle Scholar
  3. 3.
    Amin, R.P., Vickers, A.E., Sistare, F., Thompson, K.L., Roman, R.J.,Lawton, M., et al. (2004) Identification of putative gene basedmarkers of renal toxicity. Environ. Health Perspect. 112, 465–479.Google Scholar
  4. 4.
    Bailly, V., Zhang, Z., Meier, W., Cate, R., Sanicola, M., andBonventre, J.V. (2002) Shedding of kidney injury molecule-1, aputative adhesion protein involved in renal regeneration. J.Biol. Chem. 277, 39739–39748.CrossRefPubMedGoogle Scholar
  5. 5.
    Davis, J.W., Goodsaid, F.M., Bral, C.M., Obert, L.A., Mandakas, G.,Garner, C.E., et al. (2004) Quantitative gene expression analysis ina nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 200, 16–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Han, W.K., Bailly, V., Abichandani, R., Thadhani, R., and Bonventre,J.V. (2002) Kidney injury molecule-1 (KIM-1): a novel biomarker forhuman renal proximal tubule injury. Kidney Int. 62,237–244.CrossRefPubMedGoogle Scholar
  7. 7.
    Ichimura, T., Hung, C.C., Yang, S.A., Stevens, J.L., and Bonventre,J.V. (2004) Kidney injury molecule-1: a tissue and urinary biomarkerfor nephrotoxicant-induced renal injury. Am. J. Physiol. RenalPhysiol. 286, F552–F563.CrossRefGoogle Scholar
  8. 8.
    Kuehn, E.W., Park, K.M., Somlo, S., and Bonventre, J.V. (2002)Kidney injury molecule-1 expression in murine polycystic kidneydisease. Am. J. Physiol. Renal Physiol. 283, F1326–F1336.Google Scholar
  9. 9.
    Liangos, O., Perianayagam, M.C., Vaidya, V.S., Han, W.K., Wald, R.,Tighiouart, H., et al. (2007) UrinaryN-acetyl-beta-(D)-Glucosaminidase activity and kidney injurymolecule-1 level are associated with adverse outcomes in acute renalfailure. J. Am. Soc. Nephrol. 18, 904–912.CrossRefPubMedGoogle Scholar
  10. 10.
    Vaidya, V.S., Ramirez, V., Ichimura, T., Bobadilla, N.A., andBonventre, J.V. (2006) Urinary kidney injury molecule-1: a sensitivequantitative biomarker for early detection of kidney tubular injury.Am. J. Physiol. Renal Physiol. 290, F517–F529.}CrossRefPubMedGoogle Scholar
  11. 11.
    Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja,G., et al. (2000) Concordance of the toxicity of pharmaceuticals inhumans and in animals. Regul. Toxicol. Pharmacol. 32,56–67.CrossRefPubMedGoogle Scholar
  12. 12.
    Evans, R.W., Williams, G.E., Baron, H.M., Deng, M.C., Eisen, H.J.,Hunt, S.A., et al. (2005) The economic implications of noninvasivemolecular testing for cardiac allograft rejection. Am. J.Transplant. 5, 1553–1558.CrossRefPubMedGoogle Scholar
  13. 13.
    Starling, R.C., Pham, M., Valantine, H., Miller, L., Eisen, H.,Rodriguez, E.R., et al. (2006) Molecular testing in the managementof cardiac transplant recipients: initial clinical experience. J. Heart Lung Transplant. 25, 1389–1395.CrossRefPubMedGoogle Scholar
  14. 14.
    Baron, C., Somogyi, R., Greller, L.D., Rineau, V., Wilkinson, P.,Cho, C.R., et al. (2007) Prediction of graft-versus-host disease inhumans by donor gene-expression profiling. PLoS Med. 4,e23.Google Scholar
  15. 15.
    Baird, A.E. (2007) Blood genomics in human stroke. Stroke 38, 694–698.Google Scholar
  16. 16.
    Burczynski, M.E. and Dorner, A.J. (2006) Transcriptional profilingof peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7, 187–202.CrossRefPubMedGoogle Scholar
  17. 17.
    McHale, C.M., Zhang, L., Hubbard, A.E., Zhao, X., Baccarelli, A.,Pesatori, A.C., et al. (2007) Microarray analysis of gene expressionin peripheral blood mononuclear cells from dioxin-exposed humansubjects. Toxicology 229, 101–113.CrossRefPubMedGoogle Scholar
  18. 18.
    Bushel, P.R., Heinloth, A.N., Li, J., Huang, L., Chou, J.W.,Boorman, G.A. et al. (2007) Blood gene expression signatures predictexposure levels. Proc. Natl. Acad. Sci U.S.A 104,18211–18216.CrossRefPubMedGoogle Scholar
  19. 19.
    Searfoss, G.H., Jordan, W.H., Calligaro, D.O., Galbreath, E.J.,Schirtzinger, L.M., Berridge, B.R., et al. (2003) Adipsin, abiomarker of gastrointestinal toxicity mediated by a functionalgamma-secretase inhibitor. J. Biol. Chem. 278,46107–46116.CrossRefPubMedGoogle Scholar
  20. 20.
    Milano, J., McKay, J., Dagenais, C., Foster-Brown, L., Pognan, F.,Gadient, R., et al. (2004) Modulation of notch processing bygamma-secretase inhibitors causes intestinal goblet cell metaplasiaand induction of genes known to specify gut secretory lineagedifferentiation. Toxicol. Sci. 82, 341–358.CrossRefPubMedGoogle Scholar
  21. 21.
    Lin, F., Zhang, P.L., Yang, X.J., Shi, J., Blasick, T., Han, W.K., et al. (2007) Human kidney injury molecule-1 (hKIM-1): a usefulimmunohistochemical marker for diagnosing renal cell carcinoma andovarian clear cell carcinoma. Am. J. Surg. Pathol. 31,371–381.CrossRefPubMedGoogle Scholar
  22. 22.
    Mendrick, D.L. and Daniels, K.K. (2007) From the bench to the clinicand back again: translational biomarker discovery using insilicomining of pharmacogenomic data. Biomarkers Med. 1, 319–333.Google Scholar
  23. 23.
    Gielen, A.W., Lobell, A., Lidman, O., Khademi, M., Olsson, T., andPiehl, F. (2005) Expression of T cell immunoglobulin- andmucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the ratnervous and immune systems. J. Neuroimmunol. 164,93–104.CrossRefPubMedGoogle Scholar
  24. 24.
    de Souza, A.J., Oriss, T.B., O’malley, K.J., Ray, A., and Kane, L.P.(2005) T cell Ig and mucin 1 (TIM-1) is expressed on invivo-activated T cells and provides a costimulatory signal for Tcell activation. Proc. Natl. Acad. Sci U. S. A. 102,17113–17118.CrossRefPubMedGoogle Scholar
  25. 25.
    Meyers, J.H., Sabatos, C.A., Chakravarti, S., and Kuchroo, V.K.(2005) The TIM gene family regulates autoimmune and allergicdiseases. Trends Mol. Med. 11, 362–369.CrossRefPubMedGoogle Scholar
  26. 26.
    Thompson, K.L., Afshari, C.A., Amin, R.P., Bertram, T.A., Car, B.,Cunningham, M., et al. (2004) Identification of platform-independentgene expression markers of cisplatin nephrotoxicity. Environ.Health Perspect. 112, 488–494.CrossRefPubMedGoogle Scholar
  27. 27.
    Emanuelli, G., Anfossi, G., Calcamuggi, G., Marcarino, C., Ottone,G., and Dughera, L. (1985) Urinary enzyme excretion in acute andsubacute experimental lithium administration. Enzyme 34,177–185.PubMedGoogle Scholar
  28. 28.
    Cornin, R.E. and Henrich, W.L.(1996) Toxic nephropathy. In: TheKidney(Brenner, B.M., ed.), W.B. Saunders, Philadelphia,pp. 1680–1711.Google Scholar
  29. 29.
    Goldstein, R.S. and Schnellmann, R.G.(1996) Toxic responses of thekidney. In: Toxicology. The Basic Science of Poisons(Klaassen, C.D., ed.), McGraw-Hill, New York, pp. 417–442.Google Scholar
  30. 30.
    Friedl, A., Stoesz, S.P., Buckley, P., and Gould, M.N. (1999)Neutrophil gelatinase-associated lipocalin in normal and neoplastichuman tissues. Cell type-specific pattern of expression. Histochem. J. 31, 433–441.Google Scholar
  31. 31.
    Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J.,et al. (2003) Identification of neutrophil gelatinase-associatedlipocalin as a novel early urinary biomarker for ischemic renalinjury. J. Am. Soc. Nephrol. 14, 2534–2543.CrossRefPubMedGoogle Scholar
  32. 32.
    Schmidt-Ott, K.M., Mori, K., Li, J.Y., Kalandadze, A., Cohen, D.J.,Devarajan, P., and Barasch, J. (2007) Dual action of neutrophilgelatinase-associated lipocalin. J. Am. Soc. Nephrol. 18, 407–413.Google Scholar
  33. 33.
    Lau, L.F. and Lam, S.C. (1999) The CCN family of angiogenicregulators: the integrin connection. Exp. Cell Res. 248,44–57.CrossRefPubMedGoogle Scholar
  34. 34.
    Menendez, J.A., Mehmi, I., Griggs, D.W., and Lupu, R. (2003) Theangiogenic factor CYR61 in breast cancer: molecular pathology andtherapeutic perspectives. Endocr. Relat. Cancer 10,141–152.CrossRefPubMedGoogle Scholar
  35. 35.
    Muramatsu, Y., Tsujie, M., Kohda, Y., Pham, B., Perantoni, A.O.,Zhao, H., et al. (2002) Early detection of cysteine rich protein 61(CYR61, CCN1) in urine following renal ischemic reperfusion injury.Kidney Int. 62, 1601–1610.CrossRefPubMedGoogle Scholar
  36. 36.
    Salerno, R.A. and Lesko, L.J. (2004) Pharmacogenomics in drugdevelopment and regulatory decision-making: the Genomic DataSubmission (GDS) Proposal. Pharmacogenomics 5, 25–30.CrossRefPubMedGoogle Scholar
  37. 37.
    Leighton, J.K., DeGeorge, J., Jacobson-Kram, D., MacGregor, J.,Mendrick, D., and Worobec, A. (2004) Pharmacogenomic datasubmissions to the FDA: non-clinical case studies. Pharmacogenomics 5, 507–511.CrossRefPubMedGoogle Scholar
  38. 38.
    Trepicchio, W.L., Williams, G.A., Essayan, D., Hall, S.T., Harty,L.C., Shaw, P.M., et al. (2004) Pharmacogenomic data submissions tothe FDA: clinical case studies. Pharmacogenomics 5,519–524.CrossRefPubMedGoogle Scholar
  39. 39.
    Ruano, G., Collins, J.M., Dorner, A.J., Wang, S.J., Guerciolini, R.,and Huang, S.M. (2004) Pharmacogenomic data submissions to the FDA:clinical pharmacology case studies. Pharmacogenomics 5,513–517.CrossRefPubMedGoogle Scholar
  40. 40.
    Mendrick, D.L., Brazell, C., Mansfield, E.A., Pietrusko, R.,Barilero, I., Hackett, J., et al. (2006) Pharmacogenomics andregulatory decision making: an international perspective. Pharmacogenomics J. 6, 154–157.CrossRefPubMedGoogle Scholar
  41. 41.
    Salerno, R.A. and Lesko, L.J. (2006) Three years of promise,proposals, and progress on optimizing the benefit/risk of medicines:a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomicsworkshop. Pharmacogenomics J. 6, 78–81.CrossRefPubMedGoogle Scholar
  42. 42.
    Frueh, F.W., Rudman, A., Simon, K., Gutman, S., Reed, C., andDorner, A.J. (2006) Experience with voluntary and required genomicdata submissions to the FDA: summary report from track 1 of thethird FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J. 6, 296–300.PubMedGoogle Scholar
  43. 43.
    Simon, R. and Wang, S.J. (2006) Use of genomic signatures intherapeutics development in oncology and other diseases. Pharmacogenomics J. 6, 166–173.CrossRefPubMedGoogle Scholar
  44. 44.
    Hinman, L.M., Huang, S.M., Hackett, J., Koch, W.H., Love, P.Y.,Pennello, G., et al. (2006) The drug diagnostic co-developmentconcept paper Commentary from the 3rd FDA-DIA-PWG-PhRMA-BIOPharmacogenomics Workshop. Pharmacogenomics J. 6,375–380.CrossRefPubMedGoogle Scholar
  45. 45.
    Trepicchio, W.L., Essayan, D., Hall, S.T., Schechter, G., Tezak, Z.,Wang, S.J., et al. (2006) Designing prospective clinicalpharmacogenomic (PG) trials: meeting report on drug developmentstrategies to enhance therapeutic decision making. Pharmacogenomics J. 6, 89–94.CrossRefPubMedGoogle Scholar
  46. 46.
    Goodsaid, F. and Frueh, F. (2006) Process map proposal for thevalidation of genomic biomarkers. Pharmacogenomics 7,773–782.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Donna L. Mendrick
    • 1
  1. 1.Department of ToxicogenomicsGene Logic Inc.Gaithersburg

Personalised recommendations